ClinicalTrials.gg
Not yet recruitingNCT07941297Updated Nov 17, 2026

Virtual Reality-Based Cognitive-Motor Rehabilitation in Traumatic Brain Injury

An interventional study of Virtual Reality Color Trails Test (VR-CTT) and Additional Cognitive or Motor Rehabilitation in Traumatic Brain Injury, sponsored by Dr. Gabriel Zeilig. Not yet recruiting at 1 site in Israel. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Dr. Gabriel Zeilig · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Brain Injuries, Traumatic with a site in Israel — 9 open to participants now, 10 under way, none of them phase 3. Brain Injuries, Traumatic · Israel.

Planned enrollment
6th of 19
95 · median 52
Started
2026
with 2 others
No phase
13 of 35
5 open now
Registered
35th of 35
by date
Lead sponsor
1 of 35
Dr. Gabriel Zeilig

Among the 35 studies in Brain Injuries, Traumatic with a site in Israel, this one is the 6th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2026, is one of 13 with no phase, and was the 35th registered.

Brain Injuries, Traumatic

1,724 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

9 of the 35 studies in Brain Injuries, Traumatic with a site in Israel are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 284 Brain Injuries, Traumatic studies recruiting now, 123 (43%) set no upper age limit and 119 (42%) stop at 75 or younger; 40 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Brain Injuries, Traumatic with a site in Israel, or all of them as a file.
02

Study summary

This study aims to evaluate the feasibility, safety, and efficacy of a novel virtual reality (VR)-based cognitive-motor rehabilitation program for individuals with traumatic brain injury (TBI). The intervention uses the Virtual Reality Color Trails Test (VR-CTT), which combines cognitive tasks with upper-limb movements in an immersive virtual environment.

The study consists of two stages. The first stage is a feasibility pilot involving 15 participants who will complete three VR training sessions over one week. The second stage is a randomized controlled trial involving 80 participants allocated to either VR-CTT training combined with standard rehabilitation or a control group receiving standard rehabilitation with additional therapy time. The intervention will consist of nine sessions over three weeks.

The study will assess feasibility, safety, executive functions, upper-limb motor performance, balance, and functional outcomes.

Read the detailed description

Traumatic brain injury (TBI) frequently results in cognitive and motor impairments that affect everyday functioning. Conventional rehabilitation often addresses these domains separately, although many daily activities require their simultaneous integration. This study evaluates a rehabilitation approach based on the Virtual Reality Color Trails Test (VR-CTT), an immersive system developed at Sheba Medical Center that combines cognitive challenges with coordinated head and upper-limb movements.

The study consists of two sequential stages.

**Stage 1: Feasibility Pilot**

Fifteen participants with TBI will receive three VR-CTT training sessions over one week in addition to standard rehabilitation. Training will progress from seated tasks to more challenging standing activities according to individual abilities. This stage will assess feasibility, safety, usability, and participant satisfaction to inform implementation of the subsequent trial.

**Stage 2: Randomized Controlled Trial**

Eighty participants with TBI will be randomly assigned in a 1:1 ratio to two parallel groups. The intervention group will receive standard rehabilitation supplemented by nine VR-CTT training sessions over three weeks. Training difficulty will increase progressively through changes in cognitive demands, the number of targets, body position, and unilateral or bilateral hand use.

The control group will receive standard rehabilitation supplemented by additional cognitive or motor therapy to match the total treatment time of the intervention group.

Outcome assessments will be conducted before and after the intervention period and will include measures of executive functioning, upper-limb motor performance, balance, everyday functioning, and cognitive-motor interaction. Outcome assessors will remain blinded to group allocation during the randomized stage.

The study aims to determine whether integrated VR-based cognitive-motor training is feasible and safe and whether it improves cognitive and motor outcomes compared with conventional rehabilitation.

03

Conditions studied

  • Traumatic Brain Injury

Keywords

  • Virtual Reality
  • Cognitive-Motor Rehabilitation
  • Neurorehabilitation
  • Executive Functions
  • Upper Limb Motor Function
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

**Inclusion Criteria:**

  1. Men and women aged 18-50 years.
  2. Admitted for inpatient rehabilitation following traumatic brain injury (TBI).
  3. Glasgow Coma Scale (GCS) score of 9-15 at admission.
  4. Brain CT positive for acute intracranial trauma (including complicated mild or moderate TBI).
  5. Presence of cognitive and motor symptoms as determined by clinical evaluation.
  6. Sufficient decision-making capacity to provide .

**Exclusion Criteria:**

  1. Inability to meaningfully comprehend the study procedures (e.g., severe aphasia or cognitive impairment), as determined through a structured capacity assessment.
  2. Severe physical limitations that prevent the use of VR equipment (e.g., severe upper-limb fractures preventing controller use).
  3. History of epilepsy or seizures triggered by flashing lights.
  4. Severe visual or vestibular impairments that would make VR exposure unsafe (e.g., severe vertigo).
  5. Active psychiatric conditions (e.g., acute psychosis) likely to interfere with adherence to study procedures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
95 participants (estimated)

Study arms

  • Experimental
    Stage 1: VR-CTT Feasibility Pilot

    Fifteen participants with traumatic brain injury will receive standard rehabilitation supplemented by three VR-CTT training sessions over one week. Sessions will last approximately 45 minutes and progress from seated activities to standing activities according to participants' abilities. This stage will evaluate feasibility, safety, and usability.

    Device: Virtual Reality Color Trails Test (VR-CTT)

  • Experimental
    Stage 2: VR-CTT Training

    Forty participants will receive standard inpatient rehabilitation supplemented by nine VR-CTT training sessions over three weeks (three sessions per week, approximately 45 minutes each). Training will progressively increase cognitive and motor demands through changes in target number, task complexity, posture, and hand use.

    Device: Virtual Reality Color Trails Test (VR-CTT)

  • Active comparator
    Stage 2: Active Control

    Forty participants will receive standard inpatient rehabilitation supplemented by approximately three hours per week of additional cognitive or motor therapy with a therapist or volunteer, without VR-CTT training. The additional therapy is intended to match the total treatment time of the intervention group.

    Behavioral: Additional Cognitive or Motor Rehabilitation

Interventions

  • DeviceVirtual Reality Color Trails Test (VR-CTT)

    An immersive virtual reality-based cognitive-motor rehabilitation program using the HTC VIVE system and custom-developed VR-CTT software. Participants perform cognitive tasks involving visual search, attention, and cognitive flexibility while reaching toward virtual targets using coordinated upper-limb and head movements. Training difficulty is progressively adjusted by modifying the number of targets, cognitive demands, posture, and hand use. The intervention consists of three sessions over one week in Stage 1 and nine sessions over three weeks in Stage 2.

  • BehavioralAdditional Cognitive or Motor Rehabilitation

    Additional cognitive or motor rehabilitation exercises administered by a therapist or volunteer, supplementing standard inpatient rehabilitation. Participants receive approximately three hours of additional therapy per week over three weeks to match the total treatment time provided to the VR-CTT intervention group.

06

What researchers measure

Primary outcomes

  1. Change in Executive Function Composite Score

    Change in executive functioning assessed using a composite score derived from the Stroop Test, Rule Shift Cards Test (BADS), and Montreal Cognitive Assessment (MoCA). Standardized scores will be used to evaluate changes in executive control, including inhibition, cognitive shifting, and mental flexibility.

    Time frame: Baseline (Week 0) and post-intervention (Week 4).

  2. Change in Upper Limb Motor Function (ARAT)

    Change in upper limb motor function assessed using the Action Research Arm Test (ARAT), which evaluates upper extremity motor performance and coordination. Higher scores indicate better motor function.

    Time frame: Baseline (Week 0) and post-intervention (Week 4).

Secondary outcomes

  1. Change in Functional Status (FSE)

    Change in everyday functional outcomes assessed using the Functional Status Examination (FSE), which evaluates functional limitations following traumatic brain injury.

    Time frame: Baseline (Week 0) and post-intervention (Week 4).

  2. Change in Balance (Berg Balance Scale)

    Change in static and dynamic balance assessed using the Berg Balance Scale (BBS). Higher scores indicate better balance performance.

    Time frame: Baseline (Week 0) and post-intervention (Week 4).

  3. Change in Cognitive-Motor Performance (VR Supermarket Task)

    Change in performance on a virtual reality-based supermarket task assessing cognitive-motor integration, including divided attention and sustained attention during simulated everyday activities.

    Time frame: Baseline (Week 0) and post-intervention (Week 4).

  4. Change in Dual-Task Performance (Box and Block Test)

    Change in dual-task performance assessed using the Dual-Task Box and Block Test (BBT-DT), in which participants transfer blocks while simultaneously performing mental arithmetic.

    Time frame: Baseline (Week 0) and post-intervention (Week 4).

  5. Feasibility of VR-CTT Training

    Feasibility assessed by adherence to the planned VR-CTT training protocol, including the proportion of scheduled training sessions completed by participants.

    Time frame: During the one-week pilot intervention (Stage 1).

  6. Simulator Sickness Symptoms

    Simulator sickness symptoms, including nausea, dizziness, headache, and eyestrain, assessed after VR training sessions using the Simulator Sickness Questionnaire (SSQ).

    Time frame: After each VR training session during the one-week pilot (Stage 1).

  7. VR-CTT Usability and Participant Satisfaction

    Usability and participant satisfaction with the VR-CTT system assessed using post-training feedback questionnaires addressing comfort, ease of use, and overall experience.

    Time frame: At completion of the one-week pilot intervention (Stage 1).

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.

Of 444 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 36 months is below that.

Counting every sponsor, half of 466 studies reached it within 41 months; a quarter within 22 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 1, 2029
CompletionEst.
Dec 1, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941297
Lead sponsor
Dr. Gabriel Zeilig
Responsible party
Dr. Gabriel Zeilig (Director of Innovation in Rehabilitation, Sheba Medical Center) — Sponsor-investigator
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2029 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Amihai Gottlieb, Ph.D
Contact
amihai.gottlieb@gmail.com
+972543323180

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion